GlassScriptPhysician profile
Priya P Menon
NPI 1255424594
$8,696.68
in general payments reported to CMS, 2019-2025
48 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $1,059 · 2021: $1,382 · 2022: $958 · 2023: $1,598 · 2024: $1,710 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,703.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,269.85 | 2020-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $917.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $614.84 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $550.65 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $530.79 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $311.64 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $310.71 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $275.62 | 2023-2025 | |
| Dexcom, INC. | $264.43 | 2021-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $252.52 | 2021-2025 | Afrezza |
| Esperion Therapeutics, INC. | $251.64 | 2021-2025 | Nexletol |
| Alexion Pharmaceuticals, INC. | $244.87 | 2022-2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $234.21 | 2022-2025 | |
| Insulet Corporation | $202.51 | 2022-2025 | Omnipod |
| Antares Pharma, INC. | $201.29 | 2020-2025 | Xyosted, Tlando, Nocdurna |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.10 | 2020-2024 | Jardiance |
| Abbvie INC. | $170.85 | 2019-2025 | |
| Radius Health, INC. | $170.84 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $168.54 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $159.77 | 2019-2020 | |
| Horizon Therapeutics Plc | $132.98 | 2019-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $124.32 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $116.36 | 2019-2021 | |
| Medtronic, INC. | $87.92 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $81.65 | 2023-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $76.34 | 2021-2025 | Isturisa |
| Endo Pharmaceuticals INC. | $72.20 | 2019-2022 | |
| Beta Bionics, INC. | $71.66 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Lifescan, INC. | $69.98 | 2020-2022 | |
| Chiesi USA, INC. | $62.97 | 2024 | Mycapssa, Juxtapid |
| Halozyme INC | $53.80 | 2023 | |
| Zealand Pharma US, INC. | $51.95 | 2021 | |
| Neurocrine Biosciences, INC. | $45.52 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $38.81 | 2020-2021 | |
| Cequr Corporation | $35.88 | 2023-2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $35.57 | 2019 | |
| Ascensia Diabetes Care US INC. | $35.15 | 2024 | |
| Pfizer INC. | $32.49 | 2023 | |
| Merck Sharp & Dohme LLC | $27.15 | 2021-2022 | |
| Senseonics, Incorporated | $21.00 | 2019 | |
| Soleno Therapeutics, INC. | $19.49 | 2025 | Vykat Xr |
| Shire North American Group INC | $15.70 | 2019 | |
| Ascendis Pharma Endocrinology INC | $15.49 | 2025 | Yorvipath |
| Clarus Therapeutics INC. | $14.78 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.29 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $13.89 | 2019 | |
| Currax Pharmaceuticals LLC | $13.19 | 2020 | |
| Dynavax Technologies Corporation | $12.70 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.